MET and lung cancer: Based on our integrated cohort and the TCGA LUAD cohort, we identified 28774 high-confidence alternative splicing events (ASEs), which affected 8726 genes, including targets for tyrosine kinase inhibitors used to treat lung cancer, such as EGFR, RET, and MET (see methods) (Fig. 1b).